Press Release: Concert : Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert maintains deuruxolitinib breakthrough therapy designation from FDA for the treatment of alopecia areata.